Clinical guidelines for the treatment of attention deficit hyperactivity disorder in children and adolescents;Algoritmo del tratamiento para el trastorno por déficit de atención con hiperactividad en niños y adolescentes

Salud Mental

Volumn 28, Issue 5, 2005, Pages 1-10

  Ulloa, Rosa Elena ^a   Arroyo, Eduardo ^a   Ávila, José Manuel ^a   Cárdenas, José Antonio ^a   Cruz, Eduardo ^a   Gómez, Daniel ^a   Higuera, Félix ^a   Rivera, Federico ^a   Santos, Gabriela ^a   Velásquez, Víctor ^a   De La Peña, Francisco ^b  

^a Hospital Psiquiatrico Infantil Dr Juan N Navarro   (Mexico)

^b INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

Author keywords

Adolescents; Attention deficit hyperactivity disorder; Children; Pharmacological treatment

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; CLONIDINE; COCAINE; DOPAMINE; GLUTAMIC ACID; METHYLPHENIDATE; MODAFINIL; NICOTINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PSYCHOSTIMULANT AGENT; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADJUVANT THERAPY; ADOLESCENT; ALGORITHM; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CARDIOTOXICITY; CHILD; CHILD PSYCHIATRY; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG RELEASE; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EPILEPSY; FAMILY COUNSELING; GASTROINTESTINAL SYMPTOM; HEART CONDUCTION; HUMAN; HYPERACTIVITY; HYPERTENSION; INSOMNIA; MENTAL DISEASE; NAUSEA; PARENT; PRACTICE GUIDELINE; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RASH; REVIEW; SCHOOL; SEIZURE; SIDE EFFECT; SUBSTANCE ABUSE; SUDDEN DEATH; SUSTAINED RELEASE FORMULATION; TEACHER; TOBACCO DEPENDENCE;

EID: 29944440613     PISSN: 01853325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. Cuarta edición. (DSM-IV). Washington, 1994.
2. BANASCHEWSKI T, ROESSNER V, DITTMANN RW, SANTOSH PJ, ROTHENBERGER A: Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry, 13:102-116, 2004.
3. BARKLEY RA: Psychosocial treatment for Attention-Deficit/Hiperactivity Disorder in children. J Clin Psychiatry, 63:36-43, 2002.
4. BARKLEY RA, FISCHER M, SMALLISH L, FLETCHER K: Does the treatment of Attention-Deficit/Hyperactivity Disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics, 111:97-109, 2003.
5. CONNOR DF, FLETCHER KE, SWANSON JM: A meta-analysis of clonidine for symptoms of Attention-Deficit Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 38:1551-1559, 1999.
6. DULCAN M: Practice parameters for the assessment and treatment of children, adolescents, and adults with Attention-Deficit/Hiperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 36:85S-121S, 1998.
7. FARAONE SV, WILENS T: Does stimulant treatment lead to substance use disorders. J Clin Psychiatry, 64:9-13, 2003.
8. FISCHER M, BARKLEY RA: Childhood stimulant treatment and risk for later substance abuse. J Clin Psychiatry, 64:19-23, 2003.
9. INGRASSIA A, TURK J: The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders-a case series. Eur Child Adolesc Psychiatry, 14:34-40, 2005.
10. KLEIN-SCHWARTZ W: Trends and toxic effects from pediatric clonidine exposures. Arch Pediatr Adolesc Med, 156:392-396, 2002.
11. KRATOCHVIL CJ, HEILIGENSTEIN JH, DITTMANN R, SPENCER TJ y cols.: Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry, 41:776-784, 2002.
12. KUTCHER S, AMAN M, BROOKS SJ, BUITELAAR J y cols.: International consensus statement on Attention-Deficit/Hyperactivity Disorder (ADHD) and Disruptive Behaviour Disorders (DBDS): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol, 14:11-28, 2004.
13. MA CL, ARNSTEN AF, LI BM: Locomotor hyperactivity induced by blockade of prefrontal cortical Alpha2-adrenoceptors in monkeys. Biol Psychiatry, 57:192-195, 2005.
14. MC CLELLAN JM, WERRY JS: Evidence-based treatments in child and adolescent psychiatry: An inventory. J Am Acad Child Adolesc Psychiatry, 42:1388-1400, 2003.
15. MICHELSON D, FARIES D, WERNICKE J, KELSEY D y cols.: Atomoxetine in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108:1-9, 2001.
16. MIRANDA A, GARCIA R, PRESENTACION MJ: Factores moduladores de la eficacia de una intervención psicosocial en niños con Trastorno por Déficit de Atención con Hiperactividad. Rev Neurol, 34:S91-S97, 2002.
17. MOZES T, MEIRI G, BEN-AMITY G, SABBAGH M, WEIZMAN A: Reboxetine as an optional treatment for Hyperkinetic Conduct Disorder: A prospective open-label trial. J Child Adolesc Psychopharmacol, 15:259-269, 2005.
18. MTA COOPERATIVE GROUP: National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-Up: 24-Month outcomes of treatment strategies for Attention-Deficit/Hyperactivity Disorder. Pediatrics, 113:754-761, 2004.
19. MTA COOPERATIVE GROUP: National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-Up: Changes in effectiveness and growth after the end of treatment. Pediatrics, 113:762-769, 2004.
20. MUKADDES NM, ABALI O: Venlafaxine in children and adolescents with Attention Deficit Hyperactivity Disorder. Psychiatry Clin Neurosci, 58:92-95, 2004.
21. ORGANIZACION MUNDIAL DE LA SALUD: Décima Revisión de la Clasificación Internacional de las Enfermedades. Trastornos Mentales y del Comportamiento. MEDITOR, Madrid, 1993.
22. OTKA JE, MERCADANTE MT, SCAHILL L, LECKMAN JF: Reboxetine as a potentially effective treatment for Attention Deficit Hyperactivity Disorder. J Child Adolesc Psychopharmacol, 11:203-204, 2001.
23. OVERTOOM CCE, VERBATEN MN, KEMNER C, KENEMANS JL y cols.: Effects of Methylphenidate, desipramine, and L -Dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder. Behav Brain Res, 145:7-15, 2003.
24. PERWIEN AR, FARIES DE, KRATOCHVIL CJ, SUMNER CR y cols.: Improvement in health-related quality of life in children with ADHD: An analysis of placebo controlled studies of Atomoxetine. J Dev Behav Pediatr, 25:264-271, 2004.
25. PLISZKA SR: Non-stimulant treatment of Attention-Deficit/Hyperactivity Disorder. CNS Spect, 8:253-258, 2003.
26. PRINCE JB, WILENS TE, BIEDERMAN J, SPENCER TJ, WOZNIAK JR: Clonidine for sleep disturbances associated with Attention-Deficit Hyperactivity Disorder: A systematic chart review of 62 Cases. J Am Acad Child Adolesc Psychiatry, 35:599-605, 1996.
27. RATNER S, LAOR N, BRONSTEIN Y, WEIZMAN A, TOREN P: Six-week open-label Reboxetine treatment in children and adolescents with Attention-Deficit/ Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 44:428-433, 2005.
28. ROHDE LA, ROMAN T, HUTZ MH: Attention-Deficit/ Hyperactivity Disorder: Current aspects on pharmacogenetics. Pharmacogenomics J, 3:11-13, 2003.
29. RUGINO TA, SAMSOCK TC: Modafinil in children with Attention-Deficit Hyperactivity Disorder. Pediatr Neurol, 29:136-142, 2003.
30. RUIZ M: Trastorno por Déficit de Atención. Diagnóstico y Tratamiento. Academia Mexicans de Pediatría. Editores de Textos Mexicanos, México, 2004.
31. SPENCER T, BIEDERMAN J, WILENS T: Attention-Deficit/Hyperactivity Disorder. En: KUTCHER S (ed.). Practical Child and Adolescent Psychopharmacology. Cambridge University Press, pp 230-264, Cambridge, 2002.
32. SPENCER T, HEILIGENSTEIN JH, BIEDERMAN J, FARIES DE y cols.: Results from 2 proof-of-concept, placebo controlled studies of Atomoxetine in Children with Attention Deficit/Hiperactivity Disorder. J Clin Psychiatry, 63:1140-1147, 2002.
33. SPENCER TJ, BIEDERMAN J, WILENS TE, FARAONE SV: Novel treatments for Attention-Deficit/Hiperactivity Disorder in children. J Clin Psychiatry, 63:16-22, 2002.
34. STEIN MA, SARAMPOTE CS, WALDMAN ID, ROBB AS y cols.: A Dose-Response study of OROS methylphenidate in children with Attention-Deficit/Hyperactivity Disorder. Pediatrics, 112:e404-e413, 2003.
35. SWANSON JM, VOLKOW ND: Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behav Brain Res, 130:73-78, 2002.
36. SWANSON JM, VOLKOW ND: Serum and brain concentrations of methylphenidate: Implications for use and abuse. Neurosci Biobehav Rev, 27:615-621, 2003.
37. VOLKOW ND, INSEL TR: What are the long-term effects of methylphenidate treatment? Biol Psychiatry, 54:1307-1309, 2003.
38. WERNICKE JF, KRATOCHVIL CHJ: Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry, 63:50-55, 2002.
39. WILENS TE, FARAONE SV, BIEDERMAN J, GUNAWARDENE S: Does stimulant therapy of Attention-Deficit/Hyperactivity Disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111:179-185, 2003.